Discover
PMCB
PharmaCyte Biotech, Inc.
0.45
2 x 0.32
2 x 0.54
bid
ask
-
0.01
2.07%
10:25 AM
timesize
| Ytd | -37.82% | |
| 1y | -54.06% |
0.45
day range
0.46
0.33
52 week range
1.51
| Open | 0.46 | Prev Close | 0.46 | Low | 0.45 | High | 0.46 | Mkt Cap | 4.85M |
| Vol | 31.21K | Avg Vol | 189.23K | EPS | -2.08 | P/E | N/A | Forward P/E | -4.21 |
| Beta | 0.66 | Short Ratio | 1.09 | Inst. Own | 13.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.55 | 200-d Avg | 0.72 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 1.01M | ||
| Research and Development Expense | 60.00K | ||
| Selling, General and Administrative Expense | 946.71K | ||
| Operating Income | -1.01M | ||
| Net Income | -5.08M | ||
| Net Income Common Stock | -5.79M | ||
| Net Income Common Stock (USD) | -5.79M | ||
| Consolidated Income | -5.08M | ||
| Earnings per Basic Share | -0.54 | ||
| Earnings per Basic Share (USD) | -0.54 | ||
| Earnings per Diluted Share | -0.54 | ||
| Earning Before Interest & Taxes (EBIT) | -5.08M | ||
| Earning Before Interest & Taxes (USD) | -5.08M | ||
| Preferred Dividends Income Statement Impact | 704.62K | ||
| Weighted Average Shares | 10.74M | ||
| Weighted Average Shares Diluted | 10.74M | ||
| Balance Sheet | |||
| Cash and Equivalents | 17.74M | ||
| Cash and Equivalents (USD) | 17.74M | ||
| Investments | 18.50M | ||
| Investments Current | 12.77M | ||
| Investments Non-Current | 5.73M | ||
| Trade and Non-Trade Receivables | 429.15K | ||
| Current Assets | 30.97M | ||
| Total Assets | 36.71M | ||
| Current Liabilities | 768.68K | ||
| Total Liabilities | 6.90M | ||
| Accumulated Retained Earnings (Deficit) | -109.47M | ||
| Accumulated Other Comprehensive Income | -21.41K | ||
| Shareholders Equity | 27.51M | ||
| Shareholders Equity (USD) | 27.51M | ||
| Assets Non-Current | 5.74M | ||
| Liabilities Non-Current | 6.13M | ||
| Trade and Non-Trade Payables | 390.54K | ||
| Cash Flow | |||
| Net Cash Flow from Financing | -83.40K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -864.91K | ||
| Net Cash Flow from Operations | -780.89K | ||
| Effect of Exchange Rate Changes on Cash | -615.00 | ||